HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Cantor Fitzgerald reiterated an ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics ARCT in the last three months. The table below summarizes their recent ...

Arcturus is advancing its vaccine and rare disease pipeline with significant developments. The initiation of a BARDA-funded Phase 1 study for bird flu, along with ongoing studies in cystic ...

Carpenter, G D H, and Ford, E B. 1933. Mimicry. Methuen, London.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...